Column Capital Advisors’s Novo Nordisk NVO Stock Holding History

Column Capital Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$64.7K	Buy	712 +114	+19%	+$10K	0.01%	284
2023 Q2	$48.4K	Buy	598 +272	+83%	+$22.2K	0.01%	327
2023 Q1	$25.9K	Hold	326	–	–	﹤0.01%	413
2022 Q4	$22.1K	Sell	326 -12	-4%	-$704	﹤0.01%	406
2022 Q3	$17K	Buy	338 +62	+22%	+$3.32K	﹤0.01%	406
2022 Q2	$15K	Buy	276 +76	+38%	+$4.22K	﹤0.01%	420
2022 Q1	$11K	Sell	200 -60	-23%	-$3.08K	﹤0.01%	489
2021 Q4	$15K	Buy	260 +28	+12%	+$1.52K	﹤0.01%	460
2021 Q3	$11K	Buy	232 +32	+16%	+$1.55K	﹤0.01%	461
2021 Q2	$8K	Hold	200	–	–	﹤0.01%	496
2021 Q1	$7K	Hold	200	–	–	﹤0.01%	505
2020 Q4	$7K	Hold	200	–	–	﹤0.01%	502
2020 Q3	$7K	Sell	200 -594	-75%	-$19.8K	﹤0.01%	494
2020 Q2	$25K	Buy	794 +600	+309%	+$19.1K	0.01%	343
2020 Q1	$6K	Hold	194	–	–	﹤0.01%	475
2019 Q4	$5K	Buy	+194	New	+$5.37K	﹤0.01%	528

Other funds holding NVO

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Column Capital Advisors's NVO Position: Q3 2023 in Review

Column Capital Advisors increased its Novo Nordisk (NVO) stake by 19% in Q3 2023, buying an estimated $10K and bringing the position to 712 shares worth $64.7K. The position accounts for 0.01% of the portfolio, ranked #284.

Column Capital Advisors first reported a position in NVO in Q4 2019 and has held it in 16 quarters since. 1,306 funds tracked by Wall St. Rank hold NVO as of Q3 2023.

Column Capital Advisors held 712 shares of Novo Nordisk worth $64.7K as of Q3 2023.
Column Capital Advisors bought 114 Novo Nordisk shares in Q3 2023, an estimated $10K.
Novo Nordisk made up 0.01% of Column Capital Advisors's portfolio in Q3 2023, its #284 holding.
Column Capital Advisors first reported a position in Novo Nordisk in Q4 2019 and has held it in 16 quarters since.
1,306 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.